☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
akeso
Akeso Completes Patient Enrollment in P-III (HARMONi-6/AK112-306) Trial of Ivonescimab for Squamous NSCLC
February 6, 2025
China’s NMPA Accepts NDA for Akeso’s Gumokimab to Treat Moderate to Severe Psoriasis
January 27, 2025
Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024
September 9, 2024
Akeso Reports Positive Results of Cadonilimab in P-III study for the treatment of Cervical Cancer
November 28, 2023
Akeso Published P-Ia/Ib Study (COMPASSION-01) Results of Cadonilimab for Solid Tumors in Cell Reports Medicine
October 20, 2023
Akeso Reports the First Patient Dosing of Ivonescimab in P-III Trial as 1L Treatment of Squamous Non-Small Cell Lung Cancer
August 21, 2023
Akeso Published P-Ia/Ib Study (COMPASSION-01) Results of Cadonilimab for Solid Tumors in Cell Reports Medicine
October 20, 2023
PharmaShots Weekly Snapshots (August 21 – 25, 2023)
August 25, 2023
Akeso Reports the First Patient Dosing of Ivonescimab in P-III Trial as 1L Treatment of Squamous Non-Small Cell Lung Cancer
August 21, 2023
Specialised Therapeutics Collaborated with Akeso and CTTQ-Akeso to Commercialize New Anti-PD1 Antibody in Australia and Southeast...
April 12, 2023
Top 20 Life Sciences Deals of 2022 by Total Deal Value
February 8, 2023
PharmaShots' Key Highlights of Fourth Quarter 2022
December 29, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.